Mediamedic’s Post

Dr. Pashtoon Kasi, a leading figure in gastrointestinal oncology, has recently made significant strides in advancing the treatment of colorectal cancer. One of his most impactful contributions is his work on the NEST-1 clinical trial, which explored the use of botensilimab and balstilimab for patients with microsatellite stable (MSS) colorectal cancer—a subtype traditionally resistant to immunotherapy. The trial delivered remarkable results, showcasing unprecedented tumor reductions. This breakthrough opens new avenues for treating MSS colorectal cancer, a condition that has long posed challenges for oncologists. Dr. Kasi’s expertise also extends to the application of liquid biopsies using circulating tumor DNA (ctDNA). This cutting-edge approach enables real-time monitoring of cancer progression and provides valuable insights into tumor dynamics, paving the way for more personalized and precise treatments. With over #150 peer-reviewed publications, Dr. Kasi continues to push the boundaries of oncology, combining innovative research with a patient-centered approach. His work is transforming cancer care and improving outcomes for patients worldwide. #Oncology #ColorectalCancer #PashtoonKasi #ClinicalTrials #LiquidBiopsy #CancerResearch #MediaMedic #Immunotherapy #PrecisionMedicine

🌟 Reminder: Dr. Eric Van Cutsem's Key Contributions at ESMO 2024 🌟 As we look back on the highlights of #ESMO2024, we want to recognize the impactful contributions made by Dr. Eric Van Cutsem, a leading expert in gastrointestinal oncology. 🔍 Key Sessions: Metastatic Pancreatic Cancer Symposium: On September 13, 2024, Dr. Eric Van Cutsem Cutsem spoke at a Servier-sponsored symposium where he discussed the latest advancements in treating metastatic pancreatic cancer. The session featured insights from recent studies, including Napoli 3 and NALLONG, which are shaping treatment guidelines for this difficult-to-treat cancer. Rectal Cancer Session: On September 15, 2024, during a session on "Optimal Perioperative Systemic Treatment in Different Tumors", Dr. Eric Van Cutsem shared his expertise on managing rectal cancer. He highlighted the complexities of perioperative treatment decisions and the potential benefits of novel therapies in improving patient outcomes. These presentations reflect Dr. Eric Van Cutsem 's dedication to advancing treatment strategies for gastrointestinal cancers and driving innovation in clinical practice. For more insights from the conference, stay tuned for upcoming updates from #ESMO2024. #Oncology #GastrointestinalCancer #PancreaticCancer #RectalCancer #CancerResearch #EricVanCutsem #ESMO #PerioperativeTreatment #GIOncology

ESMO recommendations for the use of NGS for patients with advanced cancer which includes the use of tumour NGS to detect tumour-agnostic alterations in patients with metastatic cancers where access to matched therapies is available 🧬 #cancer #genomics #cancergenomics #NGS #stratifiedmedicine 👇🏼 https://lnkd.in/eupyGEbs

Significant advancements were showcased at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, including countless studies on its liquid biopsy technology and real-world data. Key findings from Guardant Health included improved targeted therapy selection and outcomes for advanced breast cancer. The PICI’s RADIOHEAD study highlighted the correlation between epigenomic biomarkers and immunotherapy response across 13 cancer types. Another impactful study using liquid biopsy examined racial differences in genomic profiles and treatment use in ER+ HER2- metastatic breast cancer, emphasizing the potential of epigenomic analysis to enhance treatment responses. Breast Cancer Canada was excited to see progress in pan-cancer detection, further solidifying its role in precision oncology. As noted in the video, Breast Cancer Canada research at the Breast Cancer Cell and Molecular Research Laboratory at Brandon University is led by Dr. Mousumi Majumder. The work aims to detect breast cancer at earlier stages through a blood test. Dr. Majumder is focused on finding sensitive molecular markers that can identify the disease before current technologies like mammograms can. To learn more, please read our blog article here https://lnkd.in/gaXag9pe #ASCO24 #BCCatASCO24 #breastcancerresearch #breastcancerprogress #breastcancercanada

Celebrating Dr. Heinz Josef Lenz's Contributions to Oncology in 2024 Dr. Heinz Josef Lenz, a distinguished medical oncologist specializing in gastrointestinal cancers, has made significant advancements in colorectal cancer research and treatment this year. Key Achievements: Leadership in Clinical Trials: As a co-investigator of the Phase III CheckMate 8HW study, Dr. Lenz presented expanded efficacy analyses demonstrating that first-line treatment with nivolumab plus ipilimumab significantly improves progression-free survival in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Advocacy for Immunotherapy: At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, he highlighted the promising role of immunotherapy combinations as first-line treatments for metastatic colorectal cancer, emphasizing their potential to become standard care for specific patient populations. Academic Leadership: Serving as the Associate Director for Clinical Research and Co-Chair of the Gastrointestinal Oncology Program at USC Norris Comprehensive Cancer Center, Dr. Lenz continues to lead innovative research and mentor the next generation of oncologists. #Oncology #ColorectalCancer #HeinzJosefLenz #CheckMate8HW #ASCO2024

Only biliary tract and ovarian advanced cancer patients seem to benefit from next-generation sequencing - Piotr J. Wysocki The Lancet https://lnkd.in/gJvunR9S Authors: Alberto Hernando Calvo, Paul Nguyen, Philippe L. Bedard, Kelvin K W CHAN, Ramy R. Saleh, Deirdre Weymann, Celeste Yu, Eitan Amir, Dean A Regier, Bishal Gyawali, Danielle Kain, Brooke Wilson, Craig Earle, Nicole Mittmann, Albiruni R. Abdul Razak, Wanrudee Isaranuwatchai, Peter Sabatini, Anna Spreafico, Tracy L. Stockley, Trevor J. Pugh,Christine Williams, Lillian Siu, Timothy P. Hanna #oncodaily #oncology #cancer #NGStesting #precisionmedicine #cancertreatment #clinicalresearch #patientoutcomes #OCTANEtrial #genomicmedicine #ovariancancer #biliarytractcancer #medicalresearch

Highlights ESMO updates the recommendations for the use of tumour NGS in patients with advanced cancers in routine practice ESMO expands tumour NGS recommendation to breast cancer, GIST, sarcoma, thyroid cancer, and cancer of unknown primary ESMO recommends tumour NGS for detecting tumour-agnostic alterations where matched therapies are accessible Tumour NGS should be done in clinical research centres and may be discussed under specific circumstances with patients #ESMO #Recommendations #NGS

🔬 Exciting News in Oncology Research! 🔬 At Lampgen Clinical Research, we are always on the lookout for groundbreaking advancements in cancer therapy that could potentially reshape clinical trial landscapes. A recent phase 1 trial led by Mustang Bio and City of Hope has shown promising results in treating recurrent glioblastoma with CAR-T therapy. This study, the largest of its kind for glioblastoma, demonstrated stable disease or better in half of the subjects, with one patient remaining cancer-free for over five years! This trial is particularly notable for its innovative approach of injecting CAR-T cells directly into the brain tumor and cerebrospinal fluid. This method could revolutionize treatment strategies for this aggressive form of brain cancer. We are thrilled about the potential this holds for future clinical trials and the patients they serve. As a staffing firm specializing in oncology clinical research associates, Lampgen is proud to support trials that push the boundaries of current cancer treatments. We believe that with the right team and expertise, anything is possible in the fight against cancer. #OncologyResearch #ClinicalTrials #CARTherapy #Glioblastoma #CancerResearch #InnovationInCancer #ClinicalResearchAssociates #LampgenClinicalResearch #HopeInResearch #FightCancer #MedicalAdvancements

We’re looking forward to connecting with everyone at the American Association for Cancer Research 2024 annual meeting this coming week.   The Cardiff Oncology team will be presenting five abstracts that delve into the potential of onvansertib across various cancer types.   Here’s a preview: 💡 Abstract No. 2031: A phase 1b/2 clinical study of onvansertib in combination with FOLFIRI/bevacizumab revealed a new role of PLK1 in regulating the hypoxia pathway in KRAS-mutant colorectal cancer   💡 Abstract No. CT275: A phase 2, randomized, open-label study of onvansertib in combination with standard-of-care (SoC) versus SoC alone for first-line treatment of RAS-mutant metastatic #colorectalcancer(mCRC) 💡 Abstract No. 1934: The PLK1 inhibitor, onvansertib, is active as monotherapy and in combination with cetuximab in RAS wild-type colorectal cancer patient-derived xenografts  💡 Abstract No. 606: The PLK1 inhibitor, onvansertib, synergizes with paclitaxel in #smallcell lung cancer   💡 Abstract No. 945: In vivo anti-tumor activity of onvansertib, a PLK1 inhibitor, combined with gemcitabine or carboplatin in platinum-resistant ovarian carcinoma patient-derived xenograft models   For more information about our posters, visit our website: https://ow.ly/qVVv50QNL8i.   #AACR24 #cancerresearch #ovariancancer

#PaperSpotlight: On July 2, 2024, researchers Jun Zhang, Lanlan Zhou, Shuai Zhao, and Wafik S. El-Deiry from Fox Chase Cancer Center and Brown University published a new research paper in Oncotarget, entitled, “Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or BRAF mutational status.” “In this study, we investigated the therapeutic effects and the underlying mechanisms of TAS-102 in combination with regorafenib against gastrointestinal cancers.” #PressRelease: https://lnkd.in/eQyqmYHk #cancer #colorectalcancer #gastrointestinal #drugdiscovery #regorafenib #openaccess #openscience #peerreviewed #journal #publication #publishing